Miragen Therapeutics, Inc. (NASDAQ:MGEN) marched up 5.91% compared to a 52-week low price of $2.2. The shares were last seen trading -4.12% lower, taking the closing price at $2.33 on 5/30/2019. At a recent session, the prices were hovering between $2.26 and $2.47. This company shares are 548.07% off its target price of $15.1 and the current market capitalization stands at $70.23M. The recent change has given its price a -19.83% deficit over SMA 50 and -70.65% deficit over its 52-week high. The stock witnessed -20.48% declines, -16.79% declines and -30.86% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found MGEN’s volatility during a week at 7.26% and during a month it has been found around 6.9%.Miragen Therapeutics, Inc. (MGEN) Top Holders
Institutional investors currently hold around $32 million or 45.2% in MGEN stock. Look at its top three institutional owners: Atlas Venture Advisors, Inc. owns $7.64 million in Miragen Therapeutics, Inc., which represents roughly 10.87% of the company’s market cap and approximately 23.86% of the institutional ownership. Similar statistics are true for the second largest owner, Fmr Llc, which owns 2,888,656 shares of the stock are valued at $7.02 million. The third largest holder is 683 Capital Management, Llc, which currently holds $4.29 million worth of this stock and that ownership represents nearly 6.11% of its market capitalization.
At the end of March reporting period, 21 institutional holders increased their position in Miragen Therapeutics, Inc. (NASDAQ:MGEN) by some 332,089 shares, 21 decreased positions by 1,761,027 and 16 held positions by 11,148,581. That puts total institutional holdings at 13,241,697 shares, according to SEC filings. The stock grabbed 2 new institutional investments totaling 83,179 shares while 8 institutional investors sold out their entire positions totaling 1,518,345 shares.Miragen Therapeutics, Inc. (NASDAQ:MGEN) Insider Trades
Multiple company employees have indulged in significant insider trading. Miragen Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Hughes Thomas E. has acquired 10,000 shares of Miragen Therapeutics, Inc. (MGEN) in the trading session dated Oct. 11, 2018. These shares are worth $47,700 and were traded at $4.77 each. The SEC filing shows that Levy Adam Scott performed a purchase of 9,090 shares. The Chief Business Officer added these shares by way of transaction on Feb. 13, 2018. The company’s shares were assimilated at $5.5 per share worth to an investment of some $49,995 to the account of Levy Adam Scott.
Director, Booth Bruce, purchased 545,454 common shares of Miragen Therapeutics, Inc. (MGEN) in the open market. In a transaction dated Feb. 13, 2018, the shares were bought at an average price of $5.5, giving away a sum of $2,999,997. After this purchase, 4,493,670 common shares of MGEN are directly owned by the insider, with total stake valued at $10,470,251.
In the transaction dated Dec. 20, 2017, a great number of shares sold came courtesy the Director; Hughes Thomas E. disposed a total of 12,000 shares at an average price of $8, amounting to approximately $96,000. The insider now directly owns 2,827 shares worth $6,587.
Several analysts have released their opinion on Miragen Therapeutics, Inc. (NASDAQ:MGEN), with 4 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.2 average brokerage recommendation [T1].